xCures Launches xACCESS – a New Module in Their AI-Assisted Clinical Platform

The new registration module facilitates expanded access to novel therapies for patients with advanced cancer while accelerating the generation of real-world data on safety and efficacy.

xCures is launching xACCESS – a new registration module for their AI-assisted clinical study platform. The module is used to enroll cancer patients and empower them, and their physicians, to make informed decisions and learn about access to treatment programs. The xCures platform uses a Master Observational Registry to efficiently run a wide variety of oncology studies and decentralized trials, prospectively generating real-world evidence.

Recommended AI News: Privitar Achieves Microsoft’s Co-Sell Ready Designation And Joins Microsoft Fast Track For ISVs Program

“xACCESS is xCures’ first patient-centric technology module, onboarding patients directly to our sponsored studies and partner programs,” stated Mika Newton, xCures’ CEO. “This is an important milestone on our journey to make the cancer treatment ecosystem work better for patients and facilitating access to the best treatment options.”

Recommended AI News: Silvaco Acquires Memory Compiler Technology Of Dolphin Design SAS

The xACCESS registration module enables rapid scaling by eliminating bottlenecks in eConsenting and acquiring medical records, providing benefits to patients, physicians, partners, payers, sponsors, and investors. The resulting Real-World Evidence (RWE) supports the assessment of safety, efficacy, and utility of investigational and approved cancer therapies.

Recommended AI News: QuoLab Technologies Announces Partnership With QGroup GmbH